03/2019

Partial victory for AbbVie in biosimilar dispute

Rheumatism drug Humira is one of pharmaceutical company AbbVie’s most valuable biosimilars. In ongoing disputes over the patent family, the European Patent Office Opposition Division finally rejected all oppositions in the oral hearing concerning the divisional application EP 2940 044. A significant aspect of the decision is the argument regarding priority.